INO
Inovio Pharmaceuticals Inc
NASDAQ: INO · HEALTHCARE · BIOTECHNOLOGY
$1.12
+0.00% today
Updated 2026-04-30
Market cap
$95.46M
P/E ratio
—
P/S ratio
1,460.95x
EPS (TTM)
$-1.81
Dividend yield
—
52W range
$1 – $3
Volume
1.8M
WallStSmart proprietary scores
18
out of 100
Grade: F
Strong Sell
Investment rating
2.7
Growth
F4.5
Quality
C2.5
Profitability
F5.0
Valuation
C+2/9
Piotroski F-Score
Weak
-22.3
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →200 stocks currently score above 75
Price targets
Analyst target
$6.97
+522.32%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy2 Buy2 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Debt/equity -1.30x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Altman Z -22.29 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-19.50M
- Revenue declining -100.00% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $10.26M | $832010.00 | $217756.00 | $65343.00 | $65340.00 |
| Net income | $-279.82M | $-135.12M | $-107.25M | $-84.95M | $3.76M |
| EPS | — | — | — | — | $-1.81 |
| Free cash flow | $-217.18M | $-124.69M | $-104.56M | $-88.92M | $-19.50M |
| Profit margin | -2,726.67% | -16,239.87% | -49,254.27% | -130,000.00% | — |
Peer comparison
Smart narrative
Inovio Pharmaceuticals Inc trades at $1.12. Our Smart Value Score of 18/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -22.29, it sits in the distress. TTM revenue stands at $65340.00.
Frequently asked questions
What is Inovio Pharmaceuticals Inc's stock price?
Inovio Pharmaceuticals Inc (INO) trades at $1.12.
Is Inovio Pharmaceuticals Inc overvalued?
Smart Value Score 18/100 (Grade F, Strong Sell).
What is the price target of Inovio Pharmaceuticals Inc (INO)?
The analyst target price is $6.97, representing +522.3% upside from the current price of $1.12.
What is Inovio Pharmaceuticals Inc's revenue?
TTM revenue is $65340.00.
Piotroski F-Score?
2/9 — weak financial health.
Altman Z-Score?
-22.29 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1,460.95x
ROE-183.50%
Beta1.70
50D MA$1.50
200D MA$1.87
Shares out0.08B
Float0.07B
Short ratio—
Avg volume1.8M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—